Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
| Title: | Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma |
|---|---|
| Authors: | David L. Bajor, Rosemarie Mick, Matthew J. Riese, Alex C. Huang, Brendan Sullivan, Lee P. Richman, Drew A. Torigian, Sangeeth M. George, Erietta Stelekati, Fang Chen, J. Joseph Melenhorst, Simon F. Lacey, Xiaowei Xu, E. John Wherry, Tara C. Gangadhar, Ravi K. Amaravadi, Lynn M. Schuchter, Robert H. Vonderheide |
| Source: | OncoImmunology, Vol 7, Iss 10 (2018) |
| Publisher Information: | Taylor & Francis Group, 2018. |
| Publication Year: | 2018 |
| Collection: | LCC:Immunologic diseases. Allergy LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | cd40, ctla4, melanoma, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP-870,893 and the CTLA-4 blocking mAb tremelimumab were dosed concomitantly every 3 weeks and 12 weeks, respectively, across four dose combinations. Two patients developed dose-limiting grade 3 immune-mediated colitis that led to the definition of the maximum tolerated dose (MTD). Other immune-mediated toxicity included uveitis (n = 1), hypophysitis (n = 1), hypothyroidism (n = 2), and grade 3 cytokine release syndrome (CRS) (n = 1). The estimated MTD was 0.2 mg/kg of CP-870,893 and 10 mg/kg of tremelimumab. In 22 evaluable patients, the objective response rate (ORR) was 27.3%: two patients (9.1%) had complete responses (CR) and four (18.2%) patients had partial responses (PR). With a median follow-up of 45 months, the median progression-free survival (PFS) was 3.2 months (95% CI, 1.3–5.1 months) and median overall survival (OS) was 23.6 months (95% CI, 11.7–35.5 months). Nine patients are long-term survivors (> 3 years), 8 of whom subsequently received other therapy including PD-1 mAb, surgery, or radiation therapy. Elevated baseline soluble CD25 was associated with shorter OS. Immunologically, treatment was associated with evidence of T cell activation and increased tumor T cell infiltration that was accomplished without therapeutic PD-1/PD-L1 blockade. These results suggest opportunities for immune activation and cancer immunotherapy beyond PD-1. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2162-402X 2162402X |
| Relation: | https://doaj.org/toc/2162-402X |
| DOI: | 10.1080/2162402X.2018.1468956 |
| Access URL: | https://doaj.org/article/db6c0d6d585d48869cc793dff12ef78a |
| Accession Number: | edsdoj.b6c0d6d585d48869cc793dff12ef78a |
| Database: | Directory of Open Access Journals |
| ISSN: | 2162402X |
|---|---|
| DOI: | 10.1080/2162402X.2018.1468956 |
| Published in: | OncoImmunology |
| Language: | English |